Study to assess the immunogenicity and safety of GSK’s investigational vaccine (GSK3277511A) when given to healthy smokers and ex-smokers after administration of Shingrix vaccine

Trial Identifier: 209538
Sponsor: GlaxoSmithKline
Start Date: April 2019
Primary Completion Date: August 2020
Study Completion Date: August 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Estonia Tallinn, Estonia, 10117
Estonia Tartu, Estonia, 51014
Estonia Tartu, Estonia, 50106
Finland Helsinki, Finland, 00029
Finland Jyvaskyla, Finland, 40100
Finland Tampere, Finland, FI-33100
Finland Turku, Finland, 20100
France Montpellier cedex 5, France, 34295
France Paris, France, 75679
France Rennes cedex 9, France, 35033
Italy, Toscana Pisa, Toscana, Italy, 56126
Italy, Veneto Verona, Veneto, Italy, 37134
Spain Madrid, Spain, 28006
Spain Madrid, Spain, 28046